(LDL-C) are a major risk factor for atherosclerotic cardiovascular diseases (CVD). LDL receptor (LDLR) binds then uptakes apolipoprotein (apo) B-containing lipoproteins, in particular LDL, thereby playing a pivotal role in regulating both intracellular and extracellular cholesterol levels. Indeed, human LDLR mutations cause familial hypercholesterolemia (FH), a common genetic disorder characterized by high LDL-C levels and substantially increased CVD risk. Furthermore, hydroxymethylglutaryl-CoA reductase inhibitors, statins, reduce LDL-C levels by enhancing LDLR expression especially in the liver, 1 the central organ in coordinating regulation of circulating cholesterol.
binding and internalization in a LDLR-dependent fashion, resulting in LDLR degradation. Gain-of-function mutations in PCSK9 accelerate hepatic LDLR degradation and therefore raise LDL-C levels to increase CVD risk. 4 In contrast, loss-of-function mutations enhance LDLR expression, lower LDL-C levels, and are associated with a substantial reduction in the incidence of CVD events. 5 Recently, inducible degrader of LDLR (Idol) has emerged as yet another molecule involved in LDLR protein degradation. 6 Idol is an E3 ubiquitin ligase for LDLR and facilitates LDLR degradation in lysosomes via polyubiquitination of LDLR. In view of these observations, both PCSK9 and Idol have been considered to be promising therapeutic targets for hypercholesterolemia.
PCSK9 and Idol expressions are transcriptionally regulated by sterol regulatory element-binding protein (SREBP) and liver X receptor (LXR), respectively. Intracellular cholesterol accumulation attenuates nuclear translocation of SREBP2, resulting in transrepression of PCSK9 and other SREBP-target genes whereas in sharp contrast, such circumstances induce an increase in cellular oxysterol levels, thereby leading to LXR activation, which in turn transactivates Idol. These observations raise the question why PCSK9 and Idol should be regulated by such opposing mechanisms depending on intracellular cholesterol levels, despite their similar molecular function of degrading of LDLR, and this has yet to be fully answered. Furthermore, it remains unclear whether, and if so how, PCSK9 and Idol affect each other.
In vivo LDLR degradation by Idol has been demonstrated only in mice, which lack cholesteryl ester transfer protein (CETP), resulting in an high-density lipoprotein (HDL)dominant lipoprotein profile. Considering the fact that in subjects with CETP deficiency, the profiles 7 and kinetic characteristics 8, 9 of overall lipoproteins are different from those of their normal counterparts, the effects of Idol on LDL metabolism should be assessed in CETP-expressing animals, such as hamsters. Furthermore, a CETP transgene reportedly resulted in decreased expression of hepatic LDLR, 10 and it is therefore possible that the effect of Idol on LDL-C levels is less robust in CETP-expressing animals.
The present study demonstrated that, in mice and hamsters, hepatic overexpression of Idol raised not only circulating LDL but also serum PCSK9 levels in a LDLR/SREBPdependent fashion.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

Hepatic Overexpression of Idol Increased LDL/Very-Low-Density Lipoprotein Levels by Delaying LDL Catabolism
We first assessed the effects of hepatic Idol overexpression on the lipoprotein profile in wild-type C57BL/6 mice. Figure 1A and 1B show that injection of adenoviral vector expressing Idol (Ad-Idol) resulted in a marked increase in Idol mRNA levels and a dramatic reduction in LDLR expression in the liver, but not peritoneal macrophages, demonstrating that systemic Ad-Idol injection yielded a high degree of Idol overexpression in the liver. Idol reportedly degrades very-low-density lipoprotein (VLDL) receptor. 11 Although Idol did not affect VLDL receptor expression levels in skeletal muscle and heart as shown in Figure A -C in the online-only Data Supplement, we could not detect VLDL receptor expression in the liver. As previously reported, 6 decreased liver LDLR expression attributable to Idol translated into marked increases in VLDL/ LDL-C levels ( Figure 1C ). In parallel with cholesterol levels, apoB levels in VLDL/LDL fractions were also raised in the Idol-expressing mice. The apoE levels in LDL/HDL fractions were also increased by Idol ( Figure 1D ). Zelcer et al 6 previously demonstrated that systemic injection of adenovirus expressing C387A mutant Idol, a catalytic center of the RING domain essential for E3 ligase activity, did not affect VLDL/LDL-C levels in mice and as shown in Figure 1E , we observed a similar phenomenon in mutant Idol-expressing mice. To further investigate the metabolic background for the increase in VLDL/LDL-C levels attributable to Idol, we performed a kinetic study using 125 I-labeled LDL. As shown in Figure 1F , hepatic Idol overexpression significantly decreased rates of LDL catabolism as compared with control (fractional catabolic rates in mice injected with adenoviral vector expressing luciferase [Ad-Luc], 0.12±0.01; Ad-Idol, 0.09±0.01 pool/hour; P<0.001).
Hepatic Overexpression of Idol Increased Circulating PCSK9 Levels
The next issue we addressed was whether hepatic Idol overexpression modulated circulating PCSK9 levels. As shown in Figure 2A -2C, intravenous injection of Ad-Idol caused a dose-dependent increase in serum total cholesterol (up to 462 mg/dL at peak from 113 mg/dL at baseline, at highest dose), triglycerides (up to 508 mg/dL at peak from 241 mg/dL at baseline, at highest dose), and apoB levels. Fastprotein liquid chromatography (FPLC) lipoprotein analyses revealed that less dramatic Idol overexpression using a lower dose of adenovirus produced a modest increase in VLDL/LDL cholesterol levels as compared with high dose adenovirus ( Figure 2D ). Figure 2E shows that hepatic Idol overexpression increased circulating PCSK9 levels (up to 1122 ng/dL at peak from 116 ng/dL at baseline, at highest dose), in a dose-dependent fashion. Interestingly, serum PCSK9 levels increased more rapidly and peaked earlier as compared with serum total cholesterol/triglyceride levels. 
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Idol-Induced Hepatic Expression of PCSK9 and SREBP2 Exhibited Different Time Courses
During 14 days of observation of hepatic LDLR, PCSK9, and SREBP2 expression after Idol injection, we noticed differential responses for these molecules between an early (4 days) and a late (14 days) time point. At the early time point, LDLR levels were reduced by Idol in a dose-dependent manner; however, PCSK9 and SREBP2 levels were unchanged ( Figure 3A ). In sharp contrast, 14 days after the injection, hepatic Idol overexpression dose dependently increased levels of PCSK9 and nuclear SREBP2 ( Figure 3B ), indicating enhanced SREBP2 activity. To further investigate underlying molecular mechanisms, we determined the expression levels of various molecules involved in LDL metabolism in the liver at these 2 time points. Findings obtained from quantitative real-time polymerase chain reaction (RT-PCR) supported the above observations in Western blots. Four days after the injection, we found that Ad-Idol was indeed dose dependently transduced in the liver ( Figure 3C ). Idol induced modest increases in the expressions of SREBP2target genes such as LDLR, hydroxymethylglutaryl-CoA reductase, Tmem97, and SREBP2 itself, but PCSK9 mRNA levels were unchanged. In contrast, at the late time point, injection of Ad-Idol, especially at the middle dose, increased expression of all SREBP2-target genes ( Figure 3D ), supporting the findings for PCSK9/SREBP2 protein levels ( Figure 3B ).
Hepatic Overexpression of Idol Increased Circulating Cholesterol and PCSK9 Levels in an LDLR-Dependent Fashion
Given the stimulatory effect of hepatic Idol overexpression on PCSK9 described above, we next assessed whether this phenomenon was dependent on presence of LDLR. As shown in Figure 4A , injection of Ad-Idol did not affect cholesterol levels among lipoprotein fractions in Ldlr−/− mice, a finding consistent with a previous study. 6 Interestingly, PCSK9 levels in Ldlr−/− mice were higher than those in wild-type mice at baseline ( Figure 4B , 916 versus 112 ng/ mL, respectively) as previously reported. 12 Also, PCSK9 levels in the latter were markedly increased (up to 1123 ng/ mL at day 8) by adenovirus injection to levels comparable with those in Idol injected Ldlr−/− mice (1208 ng/mL at day 8). Furthermore, in Ldlr−/− mice, PCSK9 levels were identical between Idol and control. Collectively, these data indicated that Idol increased circulating PCSK9 levels in an LDLR-dependent fashion. Figure 4C and 4D shows that, in contrast to wild-type mice, hepatic levels of PCSK9/SREBP2 protein and mRNA levels of SREBP-target genes, PCSK9, hydroxymethylglutaryl-CoA reductase, and SREBP2 itself, were not affected by Idol overexpression, both at days 4 ( Figure 
Idol Activated PCSK9/LDLR Promoter via SREBP/LDLR-Dependent Pathways
We next performed promoter assays using HepG2 cells and luciferase constructs containing PCSK9 and LDLR promoter to further clarify the precise mechanism for the inducible effect of Idol on PCSK9. Figure 5A shows LDLR expression levels based on presence/absence of cholesterol (Chol/25-hydroxycholesterol (25HC), LDL) and Idol, conditions used in the promoter assays. Under cholesterol depletion media, addition of cholesterol by means of 25HC and LDL markedly reduced LDLR protein expression ( Figure 5A ), which was further reduced by Idol overexpression. Idol overexpression also dramatically reduced LDLR levels even under cholesterol depletion media ( Figure 5A , left 2 lanes). As compared with cholesterol depletion media, cholesterol added by means of 25HC and LDL suppressed both PCSK9 and LDLR promoter activities ( Figure 5B ). Under cholesterol depletion, Idol significantly reduced the promoter activity of PCSK9, but not of LDLR. Under media with cholesterol added, however, Idol increased both PCSK9 and LDLR promoter activities only in the presence of LDL, but not cholesterol 25HC. Furthermore, when mutations were introduced into sterol-responsive elements, the above changes all disappeared.
Overall, these results indicate that Idol overexpression activates PCSK9/LDLR promoter via LDLR/SREBP2-dependent pathways, supporting the in vivo results.
LDLR Reduction Induced by Idol Overexpression Impaired Circulating PCSK9 Clearance
To find out why PCSK9 levels were increased at the early time point despite no change in PCSK9 expression, we performed an in vivo radiotracer study on PCSK9. As shown by the curves in Figure 5C , PCSK9 decay was slower for hepatic overexpression in Idol mice than in control mice (fractional catabolic rates in mice injected with Ad-Luc, 0.25±0.09; Ad-Idol, 0.21±0.04, P<0.05). This result was consistent with the previous observation: delayed clearance of PCSK9 in Ldlr−/− mice. 13 Taken together, these results indicate that LDLR reduction induced by Idol overexpression impairs circulating PCSK9 clearance.
Hepatic Overexpression of Idol Increased Serum Cholesterol Levels by Delaying LDL Catabolism and Raised Circulating PCSK9 Levels in Hamsters
Because mice lack CETP expression, HDL, rather than LDL, is the dominant lipoprotein ( Figure 1C) , which would be a major limitation in translating the findings of the present study into human circumstances. Therefore, we performed in vivo experiments using hamsters, which like humans are a CETP-expressing animal. As shown in Figure 6A , hamsters had comparable cholesterol levels in VLDL/LDL/HDL fractions. Ad-Idol intravenous injection resulted in increased cholesterol levels in VLDL/LDL, but not HDL, which was consistent with the findings in mice ( Figure 1C ). Similar to mice, hepatic overexpression in hamsters increased apoB content in VLDL/LDL fractions, and apoE in the HDL fraction ( Figure 6B ). Western blot analyses revealed that Idol overexpression in the liver reduced LDLR and raised PCSK9/ SREBP2 levels ( Figure 6C ). The LDL kinetic study also confirmed the effects of Idol on LDL catabolism in hamsters ( Figure 6D at peak from 67 ng/mL at baseline). Overall, the results for hamsters were consistent with those for mice, indicating that the observed effects of Idol are CETP independent.
Discussion
In the following, we summarize the putative mechanisms by which hepatic Idol overexpression increased circulating PCSK9 levels. At the early time point, Idol overexpression reduced LDLR expression and reduced LDL catabolism, resulting in LDL accumulation. Reduced LDLR expression attributable to Idol overexpression also impaired PCSK9 clearance, leading to PCSK9 accumulation. As a result, Idol overexpression positively modulated PCSK9, and the changes in both of them, in turn, accelerated LDLR degradation and increased LDL levels by decreasing LDL catabolism. At the later time point, however, increased transcriptions of SREBP2 and PCSK9 were evident. We speculate that cellular cholesterol content in the liver decreased because of reduction of hepatic LDLR expression induced by Idol, leading to SREBP2 activation, which in turn increased PCSK9 transcription and secretion. Such PCSK9 regulation translates into the stimulatory effect of statin treatment on PCSK9 transcription and secretion as previously observed in vitro 14 and in vivo 15, 16 experiments.
LDLR plays a central role in cellular cholesterol homeostasis. When cellular cholesterol levels are reduced, SREBP2 in the endoplasmic reticulum is cleaved and translocated to the nucleus, where it transactivates SREBP2-target genes, including LDLR. Under such circumstances, cellular oxysterol content is also decreased, leading to reduced Idol expression, which in turn upregulates LDLR expression. Thus, transcriptional regulation of Idol by LXR makes sense with regard to physiological cholesterol homeostasis. In contrast, PCSK9 regulation seems complex; activation of SREBP2 results in transactivation of both LDLR and PCSK9, which counteract increased LDLR expression. One possible explanation for this type of regulation is that promoted expression of PCSK9 under cholesterol depletion contributes to cholesterol homeostasis as a brake in advance, that is, an attempt made not to accumulate excess cholesterol via LDLR. Similar regulation is observed between interleukin-1 and interleukin-1 antagonist, as a brake against inflammatory acceleration. 17 In vitro promoter assays ( Figure 5 ) revealed that Idol overexpression increased the promoter activities of PCSK9 and LDLR under the presence of extracellular LDL, which was, in general, consistent with the in vivo experiments (Figure 3 ). This observation can be interpreted as Idol-mediated LDLR reduction leading to reduced cellular cholesterol levels which in turn activates SREBP2 with consequent PCSK9/LDLR transactivation. If this is the case, this raises the question; why did SREBP2 activation only occur at the later time point? (Figure 3) . Although speculative, we propose a putative mechanism in which time is needed for Idol-induced LDLR under the presence of extracellular cholesterol to cause a reduction in the cholesterol pool size in the liver. In the in vitro promoter assays ( Figure 5B) , only under cholesterol depletion did Idol attenuate the promoter activity of PCSK9, but not LDLR, and this phenomenon was independent of SREBP. The mechanisms for this remain unclear and thus deserve further studies. However, some of the findings of the in vivo study need discussion; as compared with the highest dose, the middle dose of Ad-Idol had a greater positive effect on the mRNA levels of SREBP-target genes ( Figure 3D ), whereas protein levels of SREBP2 and PCSK9 increased in an Ad-Idol dose-dependent manner ( Figure 3B ). Although we do not know the precise reasons for this phenomenon at present, unknown compensatory mechanisms counteracting the highest dose of Ad-Idol could be involved.
LXR activation in macrophages has recently been receiving increased attention as a promising therapeutic target against atherosclerotic diseases because it directly stimulates HDL-mediated cholesterol efflux via ATP-binding cassette transporter A1/G1 pathways. 18 However, development of LXR agonists has been hampered by their induction of hepatic steatosis, which might be because of increased fatty acid biosynthesis via increased expression of SREBP1-c. 18 Besides, LXR agonists might also raise LDL-C levels. In this regard, Honzumi et al 19 reported that administration of a synthetic LXR ligand, TO0901317, increased LDL-C levels at a dose that did not affect triglyceride levels in rabbits. They did not assess Idol and PCSK9 expressions but TO0901317 may enhance them. In the present study, although overexpression of Idol in mice does not represent physiological conditions, our observations suggest the possibility that Idol plays an important role in LDL metabolism via a LXR pathway and could thus lead to a novel LXR-targeted therapy against atherosclerosis.
Another major finding of the present study is the interaction between Idol and PCSK9. Idol increased PCSK9 levels in serum and the liver, which together accelerated LDLR catabolism and increased LDL levels by delaying catabolism. PCSK9 reportedly facilitates LDLR protein degradation after internalization of LDLR primarily by binding to the extracellular domain, 20,21 this mechanism differing from that of Idol, which works intracellularly. 6 It has also been reported that the capability of PCSK9 to induce LDLR degradation is preserved even in cells lacking Idol, 22 indicating that Idol and PCSK9 function in complementary but independent pathways. Consistent with the findings of previous research, 13 our PCSK9 kinetic experiment revealed that LDLR deletion or inhibition impaired PCSK9 catabolism ( Figure 5C ). The resultant increase in PCSK9 acted in concert with Idol to exacerbate hypercholesterolemia, including FH, in the mice. Raal et al 16 recently demonstrated that PCSK9 levels were elevated in untreated FH patients, particularly in those with homozygous FH, as compared with the control subjects. PCSK9 levels in heterozygous FH were also higher than those in the controls; however, they seemed to be lower than those in homozygous FH. In the present study, we demonstrated that complete inhibition of LDLR expression by Idol overexpression at high dose resulted in a comparable increase in PCSK9 levels to that in Ldlr−/− mice ( Figure 4B ). In contrast, partial LDLR inhibition yielded a modest increase in PCSK9 ( Figure 2D ). These observations support the above findings in homozygous and heterozygous FH patients; namely LDLR-dependent regulation of PCSK9. Treatment of FH subjects with statins and antibodies against PCSK9 reportedly exerted additive LDL-C lowering effects. 23 Because PCSK9 inhibition or deletion might attenuate hypercholesterolemia in Idol-expressing mice, further studies using PCSK9 knockout mice or its inhibitors are needed.
Mice are the most commonly used research animal, but caution should be exercised in the interpretation of data and translation into the human setting because they lack CETP. Indeed, in subjects with CETP deficiency, the profiles 7 and kinetic characteristics 8, 9 of overall lipoproteins are unique and substantially different from their normal counterparts. Although we should be cautious in translating the findings obtained from hamsters into the human setting, the hamster model is perhaps a better alternative to the mouse model in the sense that it possesses CETP activity. Therefore, we repeated experiments using hamsters to confirm the effects of hepatic Idol overexpression, and they yielded similar findings regarding lipoprotein profiles, LDL kinetics, and circulating PCSK9 concentrations, suggesting that the effects of Idol overexpression are CETP independent.
In conclusion, the present study demonstrated for the first time that hepatic Idol overexpression increased PCSK9 via dual mechanisms, SREBP2, and LDLR-dependent pathways, which then act in concert to degrade LDLR. Furthermore, because these phenomena were independent of CETP expression, our observations may provide the basis for novel Idol-PCSK9 targeted therapies against hypercholesterolemia and CVD in humans. Figure 6 . Hepatic overexpression of Idol increases serum cholesterol levels by delaying low-density lipoprotein (LDL) catabolism and raises circulating protein convertase subtilisin/kexin type 9 (PCSK9) levels in hamsters. A-C, Seven days after intravenous injection of adenoviral vector expressing Idol (Ad-Idol) or Ad-Luc (7.5×10 8 pfu) to Syrian Golden hamsters, blood and livers were obtained. FPLC-fractions from plasma were subjected to cholesterol measurement (A) and Western blot analyses (B and C). D, Four days after intravenous injection of Ad-Idol or Ad-Luc to Syrian Golden hamsters (7.5×10 8 pfu), blood samples were obtained at the indicated time points after injection of 125 I-labeled LDL, and then the 125 I remaining in the plasma was measured by a γ-counter. The fractional catabolic rate was determined using the SAAMII program. The results are representative of 2 or more experiments and are presented as mean±SE. *P<0.001 vs Luc. Apo indicates apolipoprotein.
